Clovis Oncology Inc (NASDAQ:CLVS)

5.60
Delayed Data
As of Aug 16
 +0.40 / +7.69%
Today’s Change
4.98
Today|||52-Week Range
37.27
-68.82%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$305.5M

Company Description

Clovis Oncology, Inc. is a commercial stage biotechnology company, which engages in the acquisition, development, and commercialization of cancer treatments in the United States, Europe, and other markets. Its product development programs target specific subsets of cancer, and simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from its use. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Contact Information

Clovis Oncology, Inc.
5500 Flatiron Parkway
Boulder Colorado 80301
P:(303) 625-5000
Investor Relations:
(303) 625-5023

Employees

Shareholders

Individual stakeholders7.91%
Other institutional51.89%
Mutual fund holders41.51%

Top Executives

Patrick J. MahaffyPresident, Chief Executive Officer & Director
Daniel W. MuehlChief Financial & Accounting Officer
Gillian C. Ivers-ReadChief Regulatory Officer & Executive VP
Lindsey RolfeChief Medical Officer & Executive VP-Clinical
Paul Edward GrossChief Compliance Officer, General Counsel & EVP